These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 31097113)
1. Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes. Casey L; Singh N Surg Pathol Clin; 2019 Jun; 12(2):515-528. PubMed ID: 31097113 [TBL] [Abstract][Full Text] [Related]
2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
3. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma]. Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294 [No Abstract] [Full Text] [Related]
4. The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians. McCluggage WG; Hirschowitz L; Gilks CB; Wilkinson N; Singh N Int J Gynecol Pathol; 2017 May; 36(3):230-239. PubMed ID: 27801755 [TBL] [Abstract][Full Text] [Related]
5. The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma. Singh P; Kaushal V; Rai B; Rajwanshi A; Gupta N; Dey P; Garg R; Rohilla M; Suri V; Ghoshal S; Srinivasan R Histopathology; 2018 Mar; 72(4):619-625. PubMed ID: 28914967 [TBL] [Abstract][Full Text] [Related]
6. The secondary Müllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. Singh N; Gilks CB; Wilkinson N; McCluggage WG Pathology; 2015 Aug; 47(5):423-31. PubMed ID: 26126051 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the fallopian tubes after neoadjuvant chemotherapy: persistence of serous tubal intraepithelial carcinoma. Colón E; Carlson JW Int J Gynecol Pathol; 2014 Sep; 33(5):463-9. PubMed ID: 25083961 [TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma. Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060 [TBL] [Abstract][Full Text] [Related]
9. Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage. Singh N; Benson JL; Gan C; Anglesio M; Arora R; Faruqi AZ; Hirschowitz L; Kommoss F; Scott K; Trevisan G; Leen SLS; Wilkinson N; Gilks CB; McCluggage WG Int J Gynecol Pathol; 2018 Jul; 37(4):324-330. PubMed ID: 28787323 [TBL] [Abstract][Full Text] [Related]
10. A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. Casey L; Köbel M; Ganesan R; Tam S; Prasad R; Böhm S; Lockley M; Jeyarajah AJ; Brockbank E; Faruqi A; Gilks CB; Singh N Histopathology; 2017 Nov; 71(5):736-742. PubMed ID: 28570008 [TBL] [Abstract][Full Text] [Related]
11. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors]. Wen J; Shi JL; Shen DH; Chen YX; Song QJ Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451 [TBL] [Abstract][Full Text] [Related]
12. Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. Singh N; Gilks CB; Wilkinson N; McCluggage WG Histopathology; 2015 Sep; 67(3):331-7. PubMed ID: 25640750 [TBL] [Abstract][Full Text] [Related]
13. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912 [TBL] [Abstract][Full Text] [Related]
14. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711 [TBL] [Abstract][Full Text] [Related]
15. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708). Chung YS; Park SY; Lee JY; Park JY; Lee JW; Kim HS; Suh DS; Kim YH; Lee JM; Kim M; Choi MC; Shim SH; Lee KH; Song T; Hong JH; Lee WM; Lee B; Lee IH BMC Cancer; 2019 Apr; 19(1):341. PubMed ID: 30971221 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy for high-grade serous ovarian cancer: radiologic-pathologic correlation of response assessment and predictors of progression. Roseland ME; Ma T; Shampain KL; Stein EB; Wasnik AP; Curci NE; Sciallis AP; Uppal S; Johnson TD; Maturen KE Abdom Radiol (NY); 2024 Jun; 49(6):2040-2048. PubMed ID: 38478037 [TBL] [Abstract][Full Text] [Related]
17. [Current FIGO staging classification for cancer of ovary, fallopian tube and peritoneum]. Šišovská I; Minář L; Felsinger M; Anton M; Bednaříková M; Hausnerová J; Jandáková E; Weinberger V Ceska Gynekol; 2017; 82(3):230-236. PubMed ID: 28593778 [TBL] [Abstract][Full Text] [Related]
18. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. Lee JY; Chung YS; Na K; Kim HM; Park CK; Nam EJ; Kim S; Kim SW; Kim YT; Kim HS J Gynecol Oncol; 2017 Nov; 28(6):e73. PubMed ID: 28758379 [TBL] [Abstract][Full Text] [Related]
19. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma]. Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343 [TBL] [Abstract][Full Text] [Related]